Trials / Completed
CompletedNCT01271998
Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg TR-701 Free Acid in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.
Detailed description
No applicable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TR-701 FA | 200 mg, oral, once daily for 3 days. |
Timeline
- Start date
- 2010-12-08
- Primary completion
- 2011-01-03
- Completion
- 2011-01-03
- First posted
- 2011-01-07
- Last updated
- 2019-11-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01271998. Inclusion in this directory is not an endorsement.